

Workshop casuïstiek

Friday June 22, 2018

Robert J. De Knegt

Erasmus MC – Rotterdam, the Netherlands

r.deknegt@erasmusmc.nl

DUTCH  LIVER WEEK

2018



Disclosures


Honoraria for consulting or speaking (last 5 years):

AbbVie, BMS, Gilead, Janssen-Cilag, Medtronic,
Merck/Schering-Plough, Norgine, Roche


Research grants (last 5 years):

BMS, Janssen Cilag, Medtronic, Philips, Roche


Vrouw, 43 jr, SLE, R. immunosuppressiva




Vrouw, 43, SLE, R. immunosuppressiva
HEV-RNA + okt 2015, start ribavirine dec 2015



Vrouw, 43, SLE, R. immunosuppressiva
HEV-RNA + okt 2015, start ribavirine dec 2015



Vrouw, 43, SLE, R. immunosuppressiva HEV-RNA + okt 2015, start ribavirine dec 2015




Vrouw, 43, SLE, immunosuppressiva

Verdere beloop

- Aug 2015, HEV
- Ribavirine, met breakthrough
- Begin 2016: start sofosbuvir + ribavirine, 12 weken
- Aanvankelijk gunstig resultaat
- Maand na staken, recidief
- Daarna: staken immunosuppressiva, HEV negatief
- Vanaf 12 weken negatief, hervatten immunosuppressiva
- Moraal van het verhaal: staken immunosuppressie !

www.hcvrichtsnoer.nl




The screenshot shows a web browser window with the address bar displaying <http://www.hcvrichtsnoer.nl/>. The page title is "HCV richtsnoer". Below the title, it says "update 1 mei 2016". The main content is a table of contents with the following items:

- Inhoud**
 - Tabel met belangrijkste wijzigingen
- 1. Inleiding
 - 1.1 Aanleiding
 - 1.2 Doelstelling
 - 1.3 Totstandkoming van het richtsnoer
 - 1.4 Methodes
 - 1.5 Bewijslast
 - 1.6 Update en beschikbaarheid
- 2. Indicatie voor behandeling
 - Wie te behandelen
- 3. Geregistreerde middelen in Nederland
- 4. Behandelvoorstel onbehandelde (naïeve) patiënten
- 5. Behandelvoorstel eerder behandelde patiënten
 - 5.1 Patiënten die hebben gefaald op peginterferon-alfa en ribavirine
 - 5.2 Patiënten die hebben gefaald op DAA behandeling
- 6. Acute Hepatitis C infectie
- 7. Nierinsufficiëntie
 - Expert opinion nierinsufficiëntie
 - Paritaprevir/ritonavir, ombitasvir en dasabuvir
 - Sofosbuvir
 - Ledipasvir
 - Aanbevelingen bij nierinsufficiëntie of hemodialyse
- 8. Gedecompenseerde levercirrose
 - Dosering DAAs bij leverfunctiestoornissen
- 9. Levertransplantatie
 - 9.1 Pre-transplantatie
 - 9.2 Post-levertransplantatie
- 10. Interacties tussen geneesmiddelen
 - 10.1 Interacties
 - 10.2 Interacties met HIV medicatie
- 11. Behandeling in studieverband
- 12. Referenties
- 13. Verantwoording
 - 13.1 Juridische betekenis

The browser window also shows a taskbar at the bottom with various application icons and a system clock indicating 13:24 on 19-06-2016.

HCV-Therapy Selector: www.liverdoc.nl



The screenshot shows the LiverDoc website with a navigation bar at the top containing links for Home, Instrumenten, BIBHEP, Nieuws, Over LiverDoc, Contact, and a search bar. The main content area is divided into several sections:

- Instrumenten & Programma**: A section with a blue header and a list of instruments. The first item is the **HCV Therapy Selector app**, which is highlighted. Below it, there is a description: "De HCV Therapie Selector geeft patiënt-profiel specifieke informatie over de kans op genezing van de hepatitis C-infectie, en behandeling-specifieke informatie over bijwerkingen, kosten en vergoeding." Below this description is a list of other instruments: DocTop app, Prognose Scores, e-Consult, e-Learning, and BIBHEP programma, each with a plus icon.
- Nieuw! HCV Therapy Selector: Een gratis webbapp voor artsen en patiënten**: A large image showing a laptop and a smartphone displaying the app interface. The text "Nieuw! HCV Therapy Selector: Een gratis webbapp voor artsen en patiënten" is overlaid on the image.
- Wat is LiverDoc?**: A section with a blue header and a paragraph: "LiverDoc brengt academische kennis 'op maat van de patiënt' naar de praktijk in de eerste- en tweedelij. LiverDoc biedt arts en patiënt online besloondersteunende informatie over leverziekten. Deze ondersteuning wordt nu geleverd in het kader van het nationale project Bewustzijn, Identificatie en Behandeling van chronische Hepatitis B en C (BIBHEP)." Below this is a section for **LiverDoc Instrumenten** and **LiverDoc Programma**.
- Nieuws**: A section with a blue header and a list of news items. The first item is "Nieuw: HCV Therapy Selector app" with a sub-header "Nieuw: HCV Therapy Selector app De HCV Therapie Selector (de opvolger van de HCV SVR predictor en... [Lees verder >](#))". The second item is "Farmacotherapie behandeling Hepatitis C" with a sub-header "Farmacotherapie behandeling Hepatitis Tijdens het curriculum medicatiebeoordeling... [Lees verder >](#)". The third item is "Wordt chronische hepatitis C in Nederland voldoende behandeld?" with a sub-header "Tijdens de Hepatitis workshop GGD Haaglanden op 28 januari jl. werd de resultaten van antivirale... [Lees verder >](#)".

The bottom of the screenshot shows a Windows taskbar with various icons and a system clock indicating 13:27 on 19-06-2016.

<http://hcvsvrpredictor.liverdoc.com/#/>
www.liverdoc.nl


HCV-therapy Selector: *ga naar 'instrumenten'*

The screenshot shows the LiverDoc website with the following elements:

- Header:** LiverDoc logo (beleids ondersteuning voor artsen en patiënten), navigation links (Home, Instrumenten, BIBHEP, Nieuws, Over LiverDoc, Contact, Zoek), and a search bar.
- Left Sidebar:** A list of instruments: HCV Therapy Selector, DocTop, RisicoScores, eCaseDoc, and e-Learning.
- Main Content Area:**
 - HCV Therapy Selector App:** A section describing the web app for doctors and patients. It states that the app provides specific information about the chances of curing hepatitis C infection and treatment-specific information on side effects, costs, and reimbursement.
 - Daarnaast worden richtlijnaanbevelingen...** A paragraph explaining that the app provides specific patient profiles based on genotype, previous treatment history, and cirrhosis stage.
 - De HCV-therapie Selector is een unieke bron...** A paragraph stating that the app is a unique source of evidence-based data, intended for doctors to choose the best treatment for their patients.
 - Find out now:** A green button with the text "Find out now".
 - Hoe zijn de gegevens verkregen en gevalideerd?** A section titled "Evidence-based data" explaining that the app is based on published phase 2, 3, and 4 clinical studies, as well as summaries of international conferences (e.g., AASLD and EASL) available as of February 2016. It also mentions that the European Medicines Agency has evaluated the app's results and that the quality of the data is high (at least 80%).
- Image:** A smartphone displaying the HCV Therapy Selector app interface, which includes the title "HepC app HCV Therapy Selector" and the text "Find out which approved antiviral therapy fits your patient. Cure rates of hepatitis C infection. Adverse effect profiles. Guideline recommendations." and a "Find out now" button.

<http://hcvsvrpredictor.liverdoc.com/#/>
www.liverdoc.nl

HCV-Therapy Sepector: *ga naar 'instrumenten'*



<http://hcvsvrpredictor.liverdoc.com/#/>
www.liverdoc.nl

EASL HCV Advisor

fari Archief Wijzig Weergave Geschiedenis Bladwijzers Venster Help

EASL HCV Advisor

easl.hcvadvisor.com/app/

EASL HCV Advisor

e⁺

e indicate HCV genotype. (Required)

1A	1B	2	3	4	5	6

id

e indicate HCV viral load. If none is specified, the lowest value is assumed.

Polymorphism

e indicate if a resistance-associated substitution (RAS) is known.

UNTESTED	NEGATIVE	POSITIVE

T

Mac OS X dock with various application icons.